Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcutis Biotherapeutics (ARQT) Current Assets (2020 - 2025)

Arcutis Biotherapeutics has reported Current Assets over the past 6 years, most recently at $411.2 million for Q4 2025.

  • Quarterly results put Current Assets at $411.2 million for Q4 2025, up 22.46% from a year ago — trailing twelve months through Dec 2025 was $411.2 million (up 22.46% YoY), and the annual figure for FY2025 was $411.2 million, up 22.46%.
  • Current Assets for Q4 2025 was $411.2 million at Arcutis Biotherapeutics, up from $349.2 million in the prior quarter.
  • Over the last five years, Current Assets for ARQT hit a ceiling of $496.7 million in Q3 2022 and a floor of $281.5 million in Q3 2023.
  • Median Current Assets over the past 5 years was $374.7 million (2021), compared with a mean of $381.7 million.
  • Biggest five-year swings in Current Assets: skyrocketed 96.67% in 2021 and later crashed 43.32% in 2023.
  • Arcutis Biotherapeutics' Current Assets stood at $402.8 million in 2021, then grew by 8.6% to $437.4 million in 2022, then decreased by 24.46% to $330.4 million in 2023, then rose by 1.63% to $335.8 million in 2024, then grew by 22.46% to $411.2 million in 2025.
  • The last three reported values for Current Assets were $411.2 million (Q4 2025), $349.2 million (Q3 2025), and $332.8 million (Q2 2025) per Business Quant data.